CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Sponsor: Accuray Incorporated
This NA trial investigates Cancer of the Prostate and Prostate Cancer and is currently completed. Accuray Incorporated leads this study, which shows 12 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2023 — Jul 2024 [monthly]
Completed NA
-
Sep 2022 — Jun 2023 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Apr 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting NA
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting · Phase: PHASE2 → NA
-
Feb 2019 — Sep 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Accuray Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .